Endometrial Cancer: When Upfront Surgery Is Not an Option

Amelia Barcellini; Marianna Roccio; Concetta Laliscia; Francesca Zanellini; Diana Pettinato; Francesca Valvo; Alfredo Mirandola; Ester Orlandi; Angiolo Gadducci

doi:10.1159/000510690

Endometrial Cancer: When Upfront Surgery Is Not an Option

Oncology. 2021;99(2):65-71. doi: 10.1159/000510690. Epub 2020 Oct 8.

Authors

Amelia Barcellini¹, Marianna Roccio², Concetta Laliscia³, Francesca Zanellini², Diana Pettinato², Francesca Valvo⁴, Alfredo Mirandola⁴, Ester Orlandi⁴, Angiolo Gadducci⁵

Affiliations

¹ National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy, amelia.barcellini@cnao.it.
² Department of Obstetrics and Gynecology, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy.
³ Department of Translational Medicine, Division of Radiation Oncology, University of Pisa, Pisa, Italy.
⁴ National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy.
⁵ Department of Clinical and Experimental Medicine, Division of Gynecology and Obstetrics, University of Pisa, Pisa, Italy.

PMID: 33032278
DOI: 10.1159/000510690

Abstract

Background and Summary: The management of endometrial cancer, in an ever-older population with considerable comorbidity, remains a challenge for gynecological and radiation oncologists. Key Message: The present paper reviews literature data on treatment options for endometrial cancer patients unfit for surgery.

Keywords: Brachytherapy; Chemotherapy; Endometrial cancer; Hadrontherapy; Hormonotherapy; Medically unfit.

Publication types

Review

MeSH terms

Aged
Antineoplastic Agents, Hormonal / therapeutic use*
Brachytherapy / methods*
Clinical Trials as Topic
Endometrial Neoplasms / pathology
Endometrial Neoplasms / therapy*
Female
Frail Elderly
Humans
Neoplasm Staging

Substances

Antineoplastic Agents, Hormonal